Retatrutide + Cagrilintide Stack for Fat Loss
Investigational community stack pairing a triple incretin agonist with a long-acting amylin analog.
Why Retatrutide + Cagrilintide Stack for fat loss?
No published randomized controlled trial exists for this specific retatrutide + cagrilintide combination as of 2026. Retatrutide (LY3437943) and cagrilintide each have independent Phase 3 programs (TRIUMPH and REDEFINE/CagriSema, respectively). The combined stack is community-reported, anecdotal, and investigational; synergy has not been clinically validated.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Retatrutide + Cagrilintide Stack fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Enhanced satiety via dual incretin + amylin pathways
- Reduced visceral and hepatic fat (retatrutide component data)
Reference dosing by bodyweight
Anchored to the most-cited research dose (2000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1247–1687 mcg |
| 60–75 kg / 132–165 lb | 1530–2070 mcg |
| 75–90 kg / 165–198 lb | 1870–2530 mcg |
| 90–105 kg / 198–231 lb | 2210–2990 mcg |
| >105 kg / >231 lb | 2550–3450 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Diarrhea
- Vomiting
- Increased heart rate (mild)
- Injection-site reaction
- Injection-site histamine-type reactions / urticaria (reported by community users; clinical incidence not established)
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.